- Home
- YHGJ vs PHGE Comparison
YHGJ vs PHGE Comparison
Compare YHGJ & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- PHGE
- Stock Information
- Founded
- YHGJ 1975
- PHGE 2015
- Country
- YHGJ United States
- PHGE Israel
- Employees
- YHGJ N/A
- PHGE N/A
- Industry
- YHGJ Specialty Chemicals
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- PHGE Health Care
- Exchange
- YHGJ Nasdaq
- PHGE Nasdaq
- Market Cap
- YHGJ 14.0M
- PHGE 13.3M
- IPO Year
- YHGJ 1997
- PHGE N/A
- Fundamental
- Price
- YHGJ $0.59
- PHGE $0.71
- Analyst Decision
- YHGJ
- PHGE Strong Buy
- Analyst Count
- YHGJ 0
- PHGE 2
- Target Price
- YHGJ N/A
- PHGE $13.50
- AVG Volume (30 Days)
- YHGJ 231.9K
- PHGE 36.9K
- Earning Date
- YHGJ 02-19-2025
- PHGE 11-14-2024
- Dividend Yield
- YHGJ N/A
- PHGE N/A
- EPS Growth
- YHGJ N/A
- PHGE N/A
- EPS
- YHGJ N/A
- PHGE N/A
- Revenue
- YHGJ $18,559,000.00
- PHGE N/A
- Revenue This Year
- YHGJ N/A
- PHGE N/A
- Revenue Next Year
- YHGJ N/A
- PHGE N/A
- P/E Ratio
- YHGJ N/A
- PHGE N/A
- Revenue Growth
- YHGJ 11.78
- PHGE N/A
- 52 Week Low
- YHGJ $0.43
- PHGE $0.48
- 52 Week High
- YHGJ $1.85
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- YHGJ 46.78
- PHGE 46.33
- Support Level
- YHGJ $0.57
- PHGE $0.70
- Resistance Level
- YHGJ $0.76
- PHGE $0.80
- Average True Range (ATR)
- YHGJ 0.11
- PHGE 0.06
- MACD
- YHGJ -0.00
- PHGE -0.01
- Stochastic Oscillator
- YHGJ 4.90
- PHGE 8.00
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.